On the road: Acadia teams up with Michael J. Fox Foundation for local, patient-focused Parkinson's events

Parkinson's disease health education is going on tour with a new event series sponsored by Acadia Pharmaceuticals and the Michael J. Fox Foundation. (Radiological Society of North America)

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation. The “Parkinson’s IQ + You” series will traverse the country through this year and next, connecting with local community resources in each city.

The sessions, staffed by healthcare providers, physical and speech therapists, clinical trial teams and support and advocacy group reps, are aimed at sharing the latest news and research with patients and families as well as showing them how to access local resources.

Each event will feature a live demonstration of a typical appointment with a specialist to help the audience get insights on what to expect and how to make the most of the appointment.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Acadia looks to 'blow up the paradigm' with Parkinson's psychosis drug Nuplazid

Already scheduled are events in Atlanta, Southern California and Phoenix, all hosted by Larry Gifford, who has Parkinson’s and hosts the podcast “When Life Gives You Parkinson’s.”

"The Parkinson's IQ + You program has been uniquely designed to bring much needed support and information to the Parkinson's community. We look forward to this national series of events across the country, which will offer attendees the opportunity to interact with healthcare experts and other people with Parkinson's and their families and ask important questions about disease management," Rob Kaper, senior vice president and global head of medical affairs at Acadia, said in a news release.

RELATED: Justice Department launches probe into Acadia's Nuplazid marketing

Acadia markets antipsychotic drug Nuplazid, the first med approved to treat Parkinson’s disease psychosis. The new on-the-road educational series is the latest in Acadia’s marketing quiver for Parkinson’s, which includes an unbranded campaign begun in 2017 followed by a DTC ad campaign for Nuplazid launched late last year.

Acadia has faced safety questions about the drug, including a formal inquiry by the FDA that ended with a re-endorsement by the agency last September, and is currently undergoing a Department of Justice probe into its marketing practices. Nuplazid was approved in 2016 with a black-box warning for elderly patients with dementia-related psychosis.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.